ImmunoPrecise Antibodies Q4 2024 Earnings Report $0.40 -0.02 (-4.78%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast ImmunoPrecise Antibodies EPS ResultsActual EPS-$0.52Consensus EPS -$0.10Beat/MissMissed by -$0.42One Year Ago EPSN/AImmunoPrecise Antibodies Revenue ResultsActual Revenue$4.76 millionExpected Revenue$4.92 millionBeat/MissMissed by -$160.00 thousandYoY Revenue GrowthN/AImmunoPrecise Antibodies Announcement DetailsQuarterQ4 2024Date7/29/2024TimeN/AConference Call ResourcesIPA Earnings History This is the worst sign for the U.S. stock market in 50 years (Ad)The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone" Click here to see Dan's new, urgent warning about the U.S. market for 2025. ImmunoPrecise Antibodies Earnings HeadlinesImmunoPrecise Antibodies to Showcase at Microcap ConferenceDecember 19 at 8:51 AM | tipranks.comHC Wainwright Issues Positive Outlook for IPA EarningsDecember 15, 2024 | americanbankingnews.comThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone" December 22, 2024 | Stansberry Research (Ad)HC Wainwright Has Lowered Expectations for ImmunoPrecise Antibodies (NASDAQ:IPA) Stock PriceDecember 13, 2024 | americanbankingnews.comHC Wainwright Has Pessimistic Outlook of IPA FY2028 EarningsDecember 13, 2024 | americanbankingnews.comImmunoPrecise Antibodies Reports Q2 Results and Strategic Advances in AI-Driven Drug DiscoveryDecember 11, 2024 | markets.businessinsider.comSee More ImmunoPrecise Antibodies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunoPrecise Antibodies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunoPrecise Antibodies and other key companies, straight to your email. Email Address About ImmunoPrecise AntibodiesImmunoPrecise Antibodies (NASDAQ:IPA), together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.View ImmunoPrecise Antibodies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
